OTCPicks.com: OTCPicks.com Stocks to Watch for Tuesday, November 11th CYCL, OPTR, SGAL, KERX, PUDC

Tue. November 11, 2008; Posted: 04:30 AM

Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

CENTENNIAL COMMUNICATIONS CORPORATIONS (NASDAQ: CYCL | Quote | Chart | News | PowerRating) "Up 102.60% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/CYCL.php

Centennial Communications (Nasdaq: CYCL), based in Wall, NJ, is a leading provider of regional wireless and integrated communications services in the United States and Puerto Rico with approximately 1.1 million wireless subscribers and 596,700 access lines and equivalents. The U.S. business owns and operates wireless networks in the Midwest and Southeast covering parts of six states. Centennial's Puerto Rico business owns and operates wireless networks in Puerto Rico and the U.S. Virgin Islands and provides facilities-based integrated voice, data and Internet solutions. Welsh, Carson, Anderson & Stowe is a significant shareholder of Centennial.

CYCL News:

November 7 - AT&T to Acquire Centennial Communications, Enhance Service for Wireless Customers and Businesses

AT&T Inc. (NYSE: T) and Centennial Communications Corp. (Nasdaq: CYCL | Quote | Chart | News | PowerRating) announced that AT&T plans to acquire Centennial, a regional provider of wireless and wired communications services, for $944 million in cash. The transaction will enhance AT&T's wireless coverage for customers in largely rural areas of the Midwest and Southeast United States and in Puerto Rico and the U.S. Virgin Islands. With the addition of Centennial's wired network in Puerto Rico, AT&T will also be able to better serve the company's business customers who operate there.

As a result of the acquisition, Centennial's 1.1 million wireless subscribers - many of them in rural areas - will have access to the wireless network with the best global coverage and to the nation's premier lineup of innovative wireless devices, including iPhone 3G, an AT&T exclusive. Centennial's customers who choose select smartphones - such as the BlackBerry BoldTM, another AT&T exclusive - and AT&T LaptopConnect cards will also enjoy free access to the nation's largest Wi-Fi network.

"Mobility is a vital investment area for AT&T and our company's biggest growth driver," said Ralph de la Vega, president and chief executive officer of AT&T Mobility and Consumer Markets. "This transaction enhances network coverage for our consumer and business customers and is expected to create long-term value for AT&T's stockholders."

"This acquisition offers important benefits for wireless customers of both AT&T and Centennial," de la Vega said. "Our existing customers will enjoy a better on-network calling experience in the current Centennial roaming areas. And Centennial customers will have access to a mobile-to-mobile network of nearly 75 million subscribers, AT&T's national and international roaming capabilities, our terrific device offerings and our great portfolio of applications and services."

The Centennial acquisition demonstrates AT&T's commitment to continuously enhance network quality and coverage for its wireless customers. The addition of Centennial's high-quality 850 MHz spectrum will improve service quality for AT&T customers in parts of Indiana, Louisiana, Michigan, Mississippi, Ohio and Texas.

Centennial also provides switched voice and high-capacity data and Internet Protocol solutions for business customers in Puerto Rico. The transaction gives AT&T a network presence in Puerto Rico and will allow the company to better serve its multinational business customers with a presence in this U.S. territory.

"Centennial has a 20-year history of doing what is best for our customers, and this transaction is a natural next step for us," said Michael J. Small, CEO of Centennial. "As a result of this merger, our wireless customers will enjoy greatly expanded network coverage and access to AT&T's wide range of innovative products and services. Our business customers will benefit from AT&T's expertise in delivering networking services and solutions to businesses of all sizes.

"I thank our associates for their dedication and hard work in always rising to the challenges of our rapidly changing industry, and I take pride that our company will become part of a world-class organization like AT&T."

Under terms of the agreement, Centennial stockholders will receive $8.50 per share for a total equity price of $944 million. Including net debt, the total enterprise value is approximately $2.8 billion. AT&T expects the proposed transaction to deliver significant value to its stockholders. The acquisition offers opportunities for synergies in areas including corporate overhead, advertising, customer care and network operations. In the first year after the transaction closes, AT&T expects minimal dilution to EPS and cash flow, driven by upfront integration costs.

The acquisition is subject to regulatory approval, the approval of Centennial's stockholders and other customary closing conditions. Welsh, Carson, Anderson & Stowe, Centennial's largest stockholder, has agreed to vote in support of this transaction. AT&T is working to obtain approvals by the end of the second quarter of 2009.

Centennial's 1.1 million wireless customers are in Puerto Rico and the U.S. Virgin Islands as well as in Kalamazoo, Cass City, Newaygo, Battle Creek, Benton Harbor, Jackson, Roscommon, Allegan, Grand Rapids, Lansing, Muskegon and Saginaw-Bay City, Mich.; Miami, Kosciusko, Huntington, Kokomo, Muncie, Anderson and Lafayette, Ind.; Lima and Findlay-Tiffin and Williams County, Ohio; Lafayette, Alexandria, Iberville, Bastrop and Lake Charles and Caldwell, West Feliciana, Beauregard and DeSoto parishes, La.; Beaumont-Port Arthur, Texas; and Claiborne and Copiah counties, Miss.

About AT&T

AT&T Inc. (NYSE: T) is a premier communications holding company. Its subsidiaries and affiliates, AT&T operating companies, are the providers of AT&T services in the United States and around the world. Among their offerings are the world's most advanced IP-based business communications services and the nation's leading wireless, high speed Internet access and voice services. In domestic markets, AT&T is known for the directory publishing and advertising sales leadership of its Yellow Pages and YELLOWPAGES.COM organizations, and the AT&T brand is licensed to innovators in such fields as communications equipment. As part of its three-screen integration strategy, AT&T is expanding its TV entertainment offerings. In 2008, AT&T again ranked No. 1 on Fortune magazine's World's Most Admired Telecommunications Company list and No. 1 on America's Most Admired Telecommunications Company list.

OPTIMER PHARMACEUTICALS INCORPORATED (NASDAQ: OPTR | Quote | Chart | News | PowerRating) "Up 95.87% in after hours trading on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/OPTR.php

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. OPT-80 is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea.

OPTR News:

November 10 - Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80

OPT-80 Achieves its Primary Endpoint of Clinical Cure with a Lower Recurrence Rate vs. Vancocin

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR | Quote | Chart | News | PowerRating) released positive top-line results from a pivotal Phase 3 clinical study of the Company's lead anti-infective drug candidate, OPT-80, in patients with Clostridium difficile Infection (CDI).

92.1% of patients treated with OPT-80 (per protocol population) achieved clinical cure vs. 89.8% for Vancocin. In addition, only 13.3% of patients treated with OPT-80 experienced a recurrence vs. 24.0% for Vancocin (p = 0.004). Patients treated with OPT-80 had a global cure (cure with no recurrence within four weeks) of 77.7%, which was greater than Vancocin at 67.1% (p = 0.006). OPT-80 was well-tolerated.

"We are very pleased with the results of this study, the first of our two pivotal Phase 3 trials. This study highlights the important differentiating features of OPT-80, including lower recurrence and higher global cure rate than Vancocin, the only FDA approved antibiotic for the treatment of CDI," commented, Michael N. Chang, Optimer's Chief Executive Officer. "I believe OPT-80 will be an important therapeutic option for CDI, an infection that currently has limited treatment options and affects more than 500,000 patients in the United States annually with growing incidence worldwide. Our next step is to complete the on-going second Phase 3 study at clinical sites in Europe and North America to support an NDA filing."

The OPT-80 clinical trial (Protocol 101.1.C.003) is the largest single comparative study ever conducted against Vancocin. The detailed data from the study will be presented at a medical conference in the near future.

The Per Protocol (Microbiologically Evaluable) Population is the patient group with CDI confirmed by diarrhea with a positive toxin assay, met all inclusion/exclusion criteria, and received at least 3 days of therapy and were considered a failure or at least 8 days of therapy and were considered a cure.

The Modified Intent-to-Treat Population is the patient group with CDI confirmed by diarrhea with a positive toxin assay and received at least one dose of study medication.

OPT-80 Clinical Study Design

In this multi-center, randomized, double-blind Phase 3 clinical trial, 629 adult subjects were enrolled. Subjects with confirmed CDI received either 200 mg OPT-80 dosed orally twice daily or 125 mg Vancocin dosed orally four times daily. This study was conducted in more than 100 clinical sites throughout North America. The objective of the study was to show that a 10-day course of OPT-80 was at least as efficacious (non-inferior) and safe as a 10-day course of Vancocin (vancomycin hydrochloride capsules, USP) for the treatment of CDI.

The primary endpoint of the study was clinical cure defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure, an exploratory endpoint, was defined as patients who were cured and did not have a recurrence.

ABOUT CLOSTRIDIUM DIFFICILE INFECTION

CDI has become a growing problem in hospitals, long-term care facilities and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Higher incidence and severity of CDI, increased treatment failures with standard therapies and the emergence of the hypervirulent BI (NAP1/027) strain of C. difficile have combined to result in greater awareness of CDI and growing concern among medical professionals and public health officials.

ABOUT OPT-80

OPT-80 is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of OPT-80 may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

SIGNALIFE / HEARTTRONICS INCORPORATED (OTCBB: SGAL | Quote | Chart | News | PowerRating) "Up 140.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/SGAL.php

HeartTronics, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. The Company uses its patented signal technology to design and develop medical devices - two of which are FDA-cleared - as well as therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

SGAL News:

November 10 - Legend Willie Gault Becomes Signalife's Co-CEO; Company Changing Name to HeartTronics, Inc.

Signalife, Inc. (OTCBB: SGAL | Quote | Chart | News | PowerRating) announced that Willie Gault, whose passion has led to the formation of Athletes for Life - the non-profit charity who sponsored heart screenings at which the lives of patients across the country have been saved, including 16-year old high school athlete Josh Nails - has been appointed co-CEO of the Company to handle all operations. On behalf of investors as well as individually, Mr. Gault has achieved numerous large mergers and acquisitions in various industries throughout the 50-United States, and manages these investment interests for a vast array of clients nationally and internationally. Prior to that, Mr. Gault was a member of the Super Bowl Champion Chicago Bears and has set and broken numerous track and field records over what now spans a 30-year athletic career.

The Company also announced that it is changing its name and marks, commensurate with the extensive screenings and Company peer supervision now being done to assist in the eradication of sudden heart attack and late stage heart disease. The new corporate name will be HeartTronics, Inc. and the new logo shall be available for viewing on the Company's website later this week. The name of the Company will be formally changed to HeartTronics, Inc. with the State of Delaware 20 days after the Company mails an information circular to its shareholders. The trading symbol and CUSIP number for the Company's stock will be concurrently changed, with the OTCBB designating the new trading symbol on the day the name change is effectuated with the Delaware Secretary of State. The Company will provide additional information on the effective date of the name change and new trading symbol and CUSIP number concurrent with the designation of a new trading symbol by the OTCBB.

Rowland Perkins, the Company's co-CEO for Administrative matters, commented: "I have never met a person besides Willie Gault who has the energy and passion toward this worthy cause of stopping the ravage of sudden cardiac death and late stage heart disease. As we have now learned, the Fidelity 100 is the only device capable of detecting the full bandwidth of pathology recommended by the American Heart Association. I am pleased that Willie has now come aboard to increase the screenings nationwide and to make them available not only to the poor (through AFL) but to affluent communities as well. Heart disease does not distinguish. It kills our citizens irrespective of socio-economic bracket, race or gender."

Mr. Gault's initial salary shall be $1.00 per annum, until the Company is profitable.

Mr. Gault also commented: "I am honored to take on this position. Every person deserves not to die suddenly. In no other disease state can it be said that "this disease can kill instantly." The exception is stroke, however, even that can be prevented by good comprehensive physician-screenings. My goal as HeartTronics' Operational CEO is to bring our abilities and technologies to all communities - affluent and (through AFL) impoverished alike. With physician's use of our Fidelity 100 heart monitor, I have seen with my own eyes and felt with my own heart the phenomenon of a life being saved. It means something to me, because my best friends - from Reggie White to Todd Bell - died at the hands of the same evil fate. Now it is time to get on with helping all of our citizenry, and in stopping disinformation from the health care community to the effect that everything is "alright," when the costs for heart disease are increasing another $50 billion this year according to the United States Government (now a staggering $450 billion spent in the United States alone, much of which is paid by Medicare). I am working closely with the public, private and philanthropic sectors to put a stop to the nonsense."

"There are lots of heart devices out there, from arrhythmia machines to CT scans. They do nothing to provide a comprehensive screening nor to lessen the cost-and-life impact of this disease. The other devices do not even claim to assist in the problem, and that is why the figures increase by tens of billions of dollars per year. These numbers are being paid out by our federal and state governments, and by the American population. I can guarantee everybody that the governments are "on to it" and actual prevention will be the wave of the future. The Fidelity 100 weighs a few pounds and is the only device capable of testing across the full range of disease-states, and in ambulatory settings as well. Please get ready when our screenings come to a hospital or facility near you."

KERYX BIOPHARMACEUTICALS INCORPORATED (NASDAQ: KERX | Quote | Chart | News | PowerRating) "Up 30.90% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/KERX.php

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERX News:

November 10 - Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results

Keryx to Host Investor Conference Call on Tuesday, November 11, 2008 at 8:30am EST

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the third quarter ended September 30, 2008.

At September 30, 2008, the Company had cash, cash equivalents, investment securities and interest receivable of $26.5 million, as compared to $64.7 million at December 31, 2007. Approximately $9.2 million of the Company's investments, at September 30, 2008, represent auction rate securities, which are classified as long-term investments.

The net loss for the third quarter ended September 30, 2008 was $6,841,000, or $0.15 per share, compared to a net loss of $19,528,000, or $0.45 per share, for the comparable quarter in 2007, representing a decrease in net loss of $12,687,000. The decrease in net loss was primarily attributable to a $11,699,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $1,860,000 decrease in expenses related to our other clinical compounds, and a $519,000 decrease in non-cash compensation expense related to equity incentive grants, partially offset by a $1,639,000 decrease in interest and other income (expense), net.

Commenting on the quarter, Michael S. Weiss, Keryx's Chairman and Chief Executive Officer, said, "During the third quarter, we continued to make progress in our Zerenex and Perifosine clinical programs, while operating with a lean overhead structure." Weiss continued, "We expect our cash burn to be approximately $3 million for the remaining three months of 2008, and intend to continue to focus our resources on creating value in our product portfolio."

On Tuesday, November 11, 2008, at 8:30am EST, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's third quarter financial results.

In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at www.keryx.com, for a period of 15 days after the call.

PUDA COAL INCORPORATED (OTCBB: PUDC | Quote | Chart | News | PowerRating) "Up 41.25% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/PUDC.php

Puda Coal, through its subsidiaries in China, supplies premium grade coking coal to the steel making industry for use in making coke. The Company currently possesses 3.5 million metric tons of annual coking coal cleaning capacity in Shanxi Province, China. Shanxi Province provides 20 - 25% of China's coal output and supplies nearly 50% of China's coke.

PUDC News:

November 10 - Puda Coal Announces Strong Third Quarter Results

Q3 Revenue Rises 83% and Net Income Climbs 94% Year over Year

Puda Coal, Inc. (OTCBB: PUDC), a supplier of China's high grade metallurgical coking coal used to make coke for the purposes of steel manufacturing, announced its strong financial results for the quarter ended September 30, 2008.

Third Quarter 2008 Highlights:

* Third quarter revenue reached a record $74.1 million, up 82.7% from the third quarter last year.

* Operating income totaled $9.0 million, up 63.1% from the third quarter last year.

* Net income was $6.5 million or $0.06 per fully diluted share, up 94.3% from $3.4 million, or $0.03 per fully diluted share, for third quarter last year.

* Sales of cleaned coal totaled 603,000 metric tons (MT), up 22.6% from third quarter last year.

* Average selling price of cleaned coal rose 35.2% to approximately $123 per MT (after adjusting for exchange rate differences) from the third quarter last year.

* Launched new corporate website: www.pudacoalinc.com.

* To present at the Rodman & Renshaw Annual Global Investment Conference in New York and conduct non-deal roadshow in the U.S. in November.

"We are extremely pleased with the significant increase in both our top and bottom line performance during the third quarter, which was the result of strong demand for our high grade coking coal and a substantial increase in selling prices," said Mr. Zhu, CEO and President of Puda Coal. "We plan to maintain a strong level of cash flow and liquidity to fuel our operations in the fourth quarter of 2008 and in 2009," added Mr. Zhu.

Results for the Third Quarter 2008

For the quarter ended September 30, 2008, total revenue was $74.1 million, up 82.7% from $40.5 million in the same quarter last year. This revenue growth was driven by larger customer order volume from existing and new clients for high-grade coking coal. Sales of cleaned coal were 603,000 MT, up 22.6% from 492,000 MT in the same period last year. The average selling price was approximately $123 (after adjusting for exchange rate differences), up 35.2% from $91 for the same quarter of 2007. The increases in tonnage sales and selling price of cleaned coal were the primary reasons for the increase in the net revenue.

Gross profit for the quarter was $10.2 million, up 53.1% from $6.7 million for the same period of 2007. Gross margin was 13.8% in the quarter, down from 16.4% in the same period last year. The 2.6 percentage point decline was attributable to an increase in the average purchase price of raw coal, which rose from $56 per ton in the third quarter of 2007 to $90 per ton in the current quarter. The increase in the average price of raw coal was partially offset by the increase in the average selling price of cleaned coal.

Operating expenses for the third quarter of 2008 were $1.2 million, up 5.1% from $1.1 million in the same period last year. Selling expenses increased 12.8% in support of the increase in net revenue, while general and administrative expenses declined 6.6%. As a percentage of net revenue, operating expenses were 1.6% in the third quarter of 2008, compared to 2.8% in the same quarter last year.

Operating income was $9.0 million, or 12.1% of revenue in the third quarter of 2008, up 63.1% from $5.5 million, or 13.6% of net revenue in the third quarter of 2007.

Interest expense and debt financing costs totaled $0.3 million in the third quarter of 2008, down from $0.9 million a year ago. This decrease was primarily due to lower non-cash expenses related to the amortization of the discount on the Company's convertible notes and warrants in the current quarter. In addition, the Company incurred a penalty of $0.4 million in the third quarter of 2007 due to a delay in the effectiveness of the registration statement related to its November 2005 private placement. The penalty was paid in shares of the Company's common stock.

During the third quarters of 2008 and 2007, the Company recorded non-cash gains of $0.1 million and $0.6 million, respectively, for the gain in fair value of the warrants issued in the November 2005 private placement.

Income tax expense increase 21.1% to $2.3 million in the third quarter of 2008 from $1.9 million in the year ago period due to the increase in operating profit at the Company's operating company, Shanxi Coal. This was partially offset by a reduction in the income tax rate to 25% from 33%, effective January 2008.

Net income was $6.5 million, or $0.06 per fully diluted share, compared to $3.4 million, or $0.03 per fully diluted share, in the third quarter of 2007.

Nine Month Results

Net revenue was $177.8 million for the nine months ended September 30, 2008, up 53.2% from $116.0 million in the same period of 2007. Gross profit was $24.3 million, or 13.7% of revenue, up 17.1% from $20.8 million, or 17.9% of revenue, for the nine months ended September 30, 2007. Operating income was $20.4 million, or 11.5% of revenue, up 19.4% from $17.1 million, or 14.7% of revenue, in the first nine months of 2007. Net income was $13.7 million, or $0.13 per fully diluted share, compared with net income of $6.5 million, or $0.07 per fully diluted share, in the nine months ended September 30, 2007.

Financial Condition

As of September 30, 2008, Puda Coal had $39.4 million in cash and cash equivalents and $63.3 million in working capital and a current ratio of 4.0:1. Long-term debt, excluding current portion, was $8.1 million and shareholders' equity stood at $68.3 million up from $48.6 million at the end of 2007.

The Company generated $22.6 million in cash from operating activities for the nine months ended September 30, 2008, compared to cash used in operating activities of $17.4 million in the same period last year. This was primarily due to a decrease in working capital needs resulting from decreased inventory. As of September 30, 2008, the Company had approximately $25.4 million in inventories, of which $12.3 million was raw materials. Business Outlook

Due to high prices for raw materials used in steel making and other economic factors, China's steel industry is currently experiencing slower production, which the Company believes will have a slight impact on its tonnage sales in the next two quarters or a relatively longer time.

In the longer term, Puda Coal believes the outlook for its coal washing operations remains attractive, as the Company has maintained a stable increased customer base and supply tunnels, and the demand for high-grade coking coal will continue to increase due to the development programs of China's western regions, which is expected to drive demand for steel in the long term. The Company is currently operating at approximately 69% utilization and has the capacity to meet the increases in future demand. In addition, the Company intends to execute its strategy of entering the coal mining business to increase profitability.

"While steel production in China is currently experiencing some softness, we believe the ongoing need for steel in China's long-term economic development will continue to drive the demand for steel. This provides significant opportunities for suppliers of cleaned coking coal like us," said Mr. Zhu. "We believe Puda Coal is particularly well positioned to capture this opportunity because of our excellent customer relationships and ability to provide our customers with large quantities of high grade cleaned coal."

Upcoming Events

Puda Coal will present at the upcoming Rodman & Renshaw Annual Global Investment Conference held November 10-12 at the New York Palace Hotel in New York City. During the conference, Puda Coal's management will be available for one-on-one meetings.

To complement its participation at the conference, Puda Coal is participating in a non-deal roadshow from November 10-14. Ms. Laby Wu, Puda Coal's Chief Financial Officer and Mr. Wenwei Tian, Puda Coal's COO and Director of Investor Relations will visit securities analysts and other investors in New York, Chicago and Dallas.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com was compensated five thousand dollars by a third party for PUDC advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Centennial Communications Corp (CYCL) click here. Centennial Communications Corp (CYCL) has Short Term PowerRatings of 5. Details on Centennial Communications Corp (CYCL) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index